• Tuberculosis and Respiratory Diseases
• /
• 제43권2호
• /
• pp.251-256
• /
• 1996

Kartagener 증후군은 역위, 부비동염 및 기관지 확장증을 보이는 질환으로 일종의 섬모운동장애증후군으로 여겨지고 있다. 저자들은 어렸을 때부터 호흡기 감염이 빈번한 젊은 여성에서 호흡부전과 우심부전을 동반한 Kartagener 증후군 1예를 경험하였기에 이에 문헌고찰과 함께 보고하는 바이다.

• Journal of Trauma and Injury
• /
• 제28권3호
• /
• pp.104-107
• /
• 2015

Purpose: Nitric oxide (NO) is a vasodilator and inhaled NO (iNO) is used in acute respiratory distress syndrome (ARDS) to improve alveolocapillary gas exchange. The mechanism to improve oxygenation is likely to redistribute blood flow from unventilated areas to ventilated areas. Though improvement of oxygenation, iNO therapy has not been shown to improve mortality and considered as only rescue therapy in severe hypoxemia. We conducted the study to investigate an efficacy of iNO in trauma patients with severe hypoxemia. Methods: We reviewed the trauma patients who underwent iNO therapy retrospectively from 2010 to 2014. Degree of hypoxemia was represented as $PaO_2/FiO_2$ ratio (PFR) and the severity of patient was represented with sequential organ failure assessment (SOFA) score. Patients were divided into the survivor group and non-survivor group according to the 28-day mortality. Results: A total of 20 patients were enrolled. The mortality of 28-day was 40%. There were no significant differences between survivor and non-survivor group in age, sex, severity of injury, PFR and SOFA score. There was significant difference in initiation time of iNO after injury (p=0.047). Maximum combinations of sensitivity and specificity for timing of iNO therapy were observed using cut-off of 3-day after injury with a sensitivity of 88% and specificity of 75%. Conclusion: Though iNO therapy does not influence the mortality, iNO therapy may decrease the mortality caused by respiratory failure in the early phase of trauma.

• Tuberculosis and Respiratory Diseases
• /
• 제49권4호
• /
• pp.514-519
• /
• 2000

저자들은 급성 호흡부전과 방사선학적으로 양측성 유리음영 및 국소적 낭성 변화를 보인 36세 남자 환자에서 임상 소견이 급격히 악화되는 경과를 보여 시행한 개흉 폐생검에서 후천성 면역 결핍증에 병발한 주폐포자충과 거대세포바이러스 동시 감염에 의한 폐렴으로 진담하고 문헌고찰과 함께 보고하는 바이다.

• Tuberculosis and Respiratory Diseases
• /
• 제73권1호
• /
• pp.1-10
• /
• 2012

Care of patients with sepsis has improved over the last decade. However, in the recent two years, there was no significant progress in the development of a new drug for critically ill patients. In January 2011, it was announced that the worldwide phase 3 randomized trial of a novel anti-Toll-like receptor-4 compound, eritoran tetrasodium, had failed to demonstrate an improvement in the mortality of patients with severe sepsis. In October 2011, Xigris (drotrecogin alfa, a recombinant activated protein C) was withdrawn from the market following the failure of its worldwide trial that had attempted to demonstrate improved outcome. These announcements were disappointing. The recent failure of 2 promising drugs to further reduce mortality suggests that new approaches are needed. A study was published showing that sepsis can be associated to a state of immunosuppression and loss of immune function in human. However, the timing, incidence, and nature of the immunosuppression remain poorly characterized, especially in humans. This emphasizes the need for a better understanding of sepsis as well as new therapeutic strategies. Many clinical experiences of the extracorporeal membrane oxygenator (ECMO) treatment for adult acute respiratory distress syndrome (ARDS) patients, which is caused by the H1N1 influenza A virus, were reported. The use of ECMO in severe respiratory failure, particularly in the treatment of adult ARDS, is occurring more commonly.

• Journal of Chest Surgery
• /
• 제57권2호
• /
• pp.225-229
• /
• 2024

Venovenous (VV) extracorporeal membrane oxygenation (ECMO) is a lifesaving technique for patients experiencing respiratory failure. When VV ECMO fails to provide adequate support despite optimal settings, alternative strategies may be employed. One option is to add another venous cannula to increase venous drainage, while another is to insert an additional arterial return cannula to assist cardiac function. Alternatively, a separate ECMO circuit can be implemented to function in parallel with the existing circuit. We present a case in which the parallel ECMO method was used in a 63-year-old man with respiratory failure due to coronavirus disease 2019, combined with cardiac dysfunction. We installed an additional venoarterial ECMO circuit alongside the existing VV ECMO circuit and successfully weaned the patient from both types of ECMO. In this report, we share our experience and discuss this method.

• Clinical and Experimental Pediatrics
• /
• 제63권1호
• /
• pp.3-7
• /
• 2020

High-flow nasal cannula (HFNC) is a relatively safe and effective noninvasive ventilation method that was recently accepted as a treatment option for acute respiratory support before endotracheal intubation or invasive ventilation. The action mechanism of HFNC includes a decrease in nasopharyngeal resistance, washout of dead space, reduction in inflow of ambient air, and an increase in airway pressure. In preterm infants, HFNC can be used to prevent reintubation and initial noninvasive respiratory support after birth. In children, flow level adjustments are crucial considering their maximal efficacy and complications. Randomized controlled studies suggest that HFNC can be used in cases of moderate to severe bronchiolitis upon initial low-flow oxygen failure. HFNC can also reduce intubation and mechanical ventilation in children with respiratory failure. Several observational studies have shown that HFNC can be beneficial in acute asthma and other respiratory distress. Multicenter randomized studies are warranted to determine the feasibility and adherence of HFNC and continuous positive airway pressure in pediatric intensive care units. The development of clinical guidelines for HFNC, including flow settings, indications, and contraindications, device management, efficacy identification, and safety issues are needed, particularly in children.

• Journal of Chest Surgery
• /
• 제39권4호
• /
• pp.304-309
• /
• 2006

배경: 간질성 폐렴(IP)은 폐암의 발생과 깊은 관련이 있으나 수술 후 경과에 미치는 영향은 아직 밝혀진 바 없다. 본 연구의 목적은 술전 간질성 폐렴과 수술 후 급성 호흡부전의 발생과의 관련성을 알아보기 위한 것이다. 대상 및 방법: 1997년 1월부터 2005년 3월까지 가톨릭대학교 의과대학 부속병원에서 근치적 수술을 시행받은 원발성 폐암환자 672예를 대상으로 후향적인 검토를 시행하였다. 수술 전 흉부 HRCT소견이나 수술 표본의 병리조직 판독서에서 간질성 폐렴이 확인된 환자들을 간질성 폐렴(IP)군으로 구분하여, 비합병(non-IP)군과의 사이에 수술 전 검사치와 암 관련 사항들을 비교 분석하였다. 또한 IP군에서는 급성 호흡부전의 발생군과 비발생군 사이에서 급성 호흡부전의 발생에 영향을 줄 수 있는 상이점들을 분석하였다. 결과: 근치적 수술을 시행 받은 672예 중 28예(4.2%)에서 수술 후 급성 호흡부전증이 합병되었으며, 672예 중 수술 전에 IP의 동반이 확인되었던 증례는 53예(7.9%)였다. IP 동반례에서는 6예(11.3%)에서 수술 후 급성 호흡부전증이 합병되었으며, IP가 없었던 619예에서는 22예(3.6%)에서 합병되었다. 급성 호흡부전증의 합병환자 28예 중 21예에서 사망하여 사망률은 75%였다. 결론: 간질성 폐렴은 폐암 수술 후 급성 호흡부전의 발생과 관련이 있다고 생각되었다.

• Tuberculosis and Respiratory Diseases
• /
• 제47권2호
• /
• pp.247-254
• /
• 1999

급성 유기인제 중독에서의 주사망 원인인 호흡부전은 급성 콜린성 위기시에 발생하지만 콜린성 위기에서 회복된 후 콜린양 증상의 동반없이 24-96시간에 근위부 사지근육, 경부굴근 및 운동뇌신경 분포근육의 무력증과 함께 호흡부전이 발생하기도 한다. 이를 IMS이라 하며 조기에 인지하고 적절히 치료하지 못했을 때 호흡근 마비로 사망 할 수 있어 모든 유기인제 중독환자를 최소 5일 이상 병원내에서 무호흡보조 치료에 대한 준비상태를 갖추고 근접관찰 하여야 한다. 저자들은 유기인제 중독에서 콜린성 위기 회복후 호흡부전을 유발한 IMS 2 례를 경험하였기에 문헌고찰과 함께 보고하는 바이다.

• Tuberculosis and Respiratory Diseases
• /
• 제61권6호
• /
• pp.562-566
• /
• 2006

지방색전증후군은 외상 등의 원인으로 발생한 지방색전에 의해 유발되는 전신 질환으로 급성호흡부전 및 의식변화를 초래할 수 있다. 저자들은 평소 질병이 없던 22세 남자로 교통사고에 의한 대퇴골 간부 및 다발성 골절을 입고 개인병원에서 외부고정장치 수술 받은 후 다음 날부터 호흡곤란과 의식저하 보여 본원에 전원된 환자에서, 증상 발현 당시는 급성호흡부전증을 동반한 지방색전증후군으로 추정 진단하고, 증상 호전 후 시행한 기관지 폐포세척액에서 대식세포내 지방과립구를 확인하여 보고한다. 급성호흡부전증의 급성기에 기관지내시경을 시행하는 것은 호흡부전의 원인 감별에 도움이 되지만 때로 환자에게 위험을 초래할 수도 있으므로, 임상적으로 지방색전증후군이 추정되는 환자에서 회복기에 기관지폐포세척검사를 시행하는 것은 확진에 도움이 될 수 있으리라 추정된다.

• Journal of Korean Neurosurgical Society
• /
• 제64권5호
• /
• pp.791-798
• /
• 2021

Objective : The period of mechanical ventilator (MV)-dependent respiratory failure after cervical spinal cord injury (CSCI) varies from patient to patient. This study aimed to identify predictors of MV at hospital discharge (MVDC) due to prolonged respiratory failure among patients with MV after CSCI. Methods : Two hundred forty-three patients with CSCI were admitted to our institution between May 2006 and April 2018. Their medical records and radiographic data were retrospectively reviewed. Level and completeness of injury were defined according to the American Spinal Injury Association (ASIA) standards. Respiratory failure was defined as the requirement for definitive airway and assistance of MV. We also evaluated magnetic resonance imaging characteristics of the cervical spine. These characteristics included : maximum canal compromise (MCC); intramedullary hematoma or cord transection; and integrity of the disco-ligamentous complex for assessment of the Subaxial Cervical Spine Injury Classification (SLIC) scoring. The inclusion criteria were patients with CSCI who underwent decompression surgery within 48 hours after trauma with respiratory failure during hospital stay. Patients with Glasgow coma scale 12 or lower, major fatal trauma of vital organs, or stroke caused by vertebral artery injury were excluded from the study. Results : Out of 243 patients with CSCI, 30 required MV during their hospital stay, and 27 met the inclusion criteria. Among them, 48.1% (13/27) of patients had MVDC with greater than 30 days MV or death caused by aspiration pneumonia. In total, 51.9% (14/27) of patients could be weaned from MV during 30 days or less of hospital stay (MV days : MVDC 38.23±20.79 vs. MV weaning, 13.57±8.40; p<0.001). Vital signs at hospital arrival, smoking, the American Society of Anesthesiologists classification, Associated injury with Injury Severity Score, SLIC score, and length of cord edema did not differ between the MVDC and MV weaning groups. The ASIA impairment scale, level of injury within C3 to C6, and MCC significantly affected MVDC. The MCC significantly correlated with MVDC, and the optimal cutoff value was 51.40%, with 76.9% sensitivity and 78.6% specificity. In multivariate logistic regression analysis, MCC >51.4% was a significant risk factor for MVDC (odds ratio, 7.574; p=0.039). Conclusion : As a method of predicting which patients would be able to undergo weaning from MV early, the MCC is a valid factor. If the MCC exceeds 51.4%, prognosis of respiratory function becomes poor and the probability of MVDC is increased.